| 32.47 -1.94 (-5.64%) | 03-12 14:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.19 |
1-year : | 42.66 |
| Resists | First : | 34.41 |
Second : | 36.52 |
| Pivot price | 33.82  |
|||
| Supports | First : | 31 |
Second : | 25.79 |
| MAs | MA(5) : | 33.48 |
MA(20) : | 33.47 |
| MA(100) : | 30.73 |
MA(250) : | 20.35 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 46.9 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 36.52 | Low : | 5.48 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORKA ] has closed above bottom band by 20.0%. Bollinger Bands are 33.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.75 - 35.89 | 35.89 - 36.04 |
| Low: | 33.16 - 33.3 | 33.3 - 33.45 |
| Close: | 34.17 - 34.42 | 34.42 - 34.68 |
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Wed, 11 Mar 2026
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - simplywall.st
Tue, 10 Mar 2026
Should Oruka’s Once-Yearly ORKA-001 Psoriasis Dosing Ambition Require Action From Oruka Therapeutics (ORKA) Investors? - Sahm
Fri, 06 Mar 2026
Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market - TipRanks
Mon, 02 Mar 2026
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Thu, 26 Feb 2026
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat
Wed, 25 Feb 2026
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 111.1 (%) |
| Shares Short | 4,060 (K) |
| Shares Short P.Month | 5,240 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 3.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.65 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 59.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|